Refining our understanding of antimicrobial peptide mediated disruption of the Klebsiella pneumoniae capsule

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 5R00AI163295-04

Grant search

Key facts

  • Disease

    Bacterial infection caused by Klebsiella pneumonia
  • Start & end year

    2021
    2026
  • Known Financial Commitments (USD)

    $249,000
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    ASSISTANT PROFESSOR Renee Fleeman
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF CENTRAL FLORIDA
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Project Summary Multi-drug resistant Klebsiella pneumoniae bacterial infections are a major threat to human health as mortality rates are steadily on the rise. One of the defining characteristics of K. pneumoniae is a robust capsule that aids in resistance to the human complement system, host antimicrobial peptides, and last resort therapeutic polymyxins. However, there have not been significant efforts to identify the attributes that allow active peptides to bypass the capsule of K. pneumoniae. I have previously discovered a novel mechanism of peptide disruption of the capsule barrier of K. pneumoniae. I hypothesize there are amino acid residues that change the physiochemical attributes and allow for penetration through the capsule. During the K99 phase of this proposal I will: 1) Define how host defense peptides fit into the novel mechanism of capsule disruption; and 2) Identify broader set of physiochemical characteristics that allow for disruption of the K. pneumoniae capsule. The objective of these aims is to determine how well studied host defense peptides fit into the mechanism of capsule disruption using biochemical and biophysical experiments and determine the physiochemical attributes that allow for peptide aggregation and disruption of K. pneumoniae capsule. The R00 phase will build on the K99 phase, to identify the structural components of bacterial capsule that is aggregating with peptides and reveal the implications of therapeutic capsule removal on the infection process of K. pneumoniae using peptides discovered in the K99 phase. The K99/R00 award will allow me to utilize the extensive resources available at the University of Texas at Austin while working with my mentor team to ensure successful transition to an independent research position. The results of the studies completed in this award will provide a greater understanding of peptide disruption of capsule and how this changes the infection process of K. pneumoniae.